Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 17/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259405 | 1.00 | PIK3C3 (0.54) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156689 | 1.00 | PIK3C3 (0.54) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL22170311 | 0.91 | PIK3C3 (0.49) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL21362955 | 0.90 | PDCD1 (0.54) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156988 | 0.87 | PIK3C3 (0.46) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156414 | 0.87 | PIK3C3 (0.46) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156125 | 0.87 | PIK3C3 (0.46) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156413 | 0.85 | PDCD1 (0.49) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156133 | 0.85 | PDCD1 (0.49) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL27132327 | 0.85 | PDCD1 (0.49) | PIK3C3PDCD1CD274ATRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673441-A1 | LZK INHIBITORS | Ureka Bioscienes, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182552-A1 | LZK INHIBITORS | UEREKA BIOSCIENCES, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2024-04-23 | — | — | US | disclosed |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Spring Bioscience AB (SE) | 2024-02-15 | — | — | US | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| CN-112218631-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-12-22 | — | — | CN | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| EP-3416957-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3416945-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | PIK3C3 3821/4885PDCD1 484/4885CD274 890/4885 |
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | PIK3C3 4621/4885PDCD1 1498/4885CD274 2397/4885 |
| US-20190282584-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | PIK3C3 545/4885PDCD1 1035/4885CD274 3017/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | PIK3C3 482/4885PDCD1 343/4885CD274 491/4885 |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | PYCR1, GPR119, CDK6 | PIK3C3 4489/4885PDCD1 289/4885CD274 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.